The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy

Douglas Norman, John Barry, W. M. Bennett, M. Leone, K. Henell, B. Funnell, B. Hubert

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Thirty-one recipients of cadaver kidney transplants were given OKT3 monoclonal anti-T cell antibody for rejection treatment after conventional therapy had failed. Seventy-four percent of steroid or steroid and antithymocyte globulin (ATG) resistant rejections reversed with a standard course of OKT3. Rejections reversed in 85% of 26 patients treated within 90 days of transplantation. Late rejections treated more than 90 days after transplantation were poorly responsive to OKT3 and graft survival for this group of five patients was poor (20%). However, for those patients treated with OKT3 for early resistant rejection, actuarial 4-year graft survival was 66%. Actuarial 4-year patient survival was 97%, and the incidence of serious infection was low. Acute rejections in cadaver transplantation are common and a small percentage of rejections are resistant to steroids and ATG. OKT3 has proven to be useful for reversing these resistant rejections without causing significant morbidity from infection or death.

Original languageEnglish (US)
Pages (from-to)90-93
Number of pages4
JournalAmerican Journal of Kidney Diseases
Volume11
Issue number2
StatePublished - 1988

Fingerprint

Muromonab-CD3
Graft Rejection
Kidney Transplantation
Immunosuppression
Antilymphocyte Serum
Transplantation
Steroids
Graft Survival
Cadaver
Infection
Morbidity
T-Lymphocytes
Transplants
Kidney
Survival
Antibodies
Incidence
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. / Norman, Douglas; Barry, John; Bennett, W. M.; Leone, M.; Henell, K.; Funnell, B.; Hubert, B.

In: American Journal of Kidney Diseases, Vol. 11, No. 2, 1988, p. 90-93.

Research output: Contribution to journalArticle

@article{6acafc6a96ac4255a43256204d266939,
title = "The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy",
abstract = "Thirty-one recipients of cadaver kidney transplants were given OKT3 monoclonal anti-T cell antibody for rejection treatment after conventional therapy had failed. Seventy-four percent of steroid or steroid and antithymocyte globulin (ATG) resistant rejections reversed with a standard course of OKT3. Rejections reversed in 85{\%} of 26 patients treated within 90 days of transplantation. Late rejections treated more than 90 days after transplantation were poorly responsive to OKT3 and graft survival for this group of five patients was poor (20{\%}). However, for those patients treated with OKT3 for early resistant rejection, actuarial 4-year graft survival was 66{\%}. Actuarial 4-year patient survival was 97{\%}, and the incidence of serious infection was low. Acute rejections in cadaver transplantation are common and a small percentage of rejections are resistant to steroids and ATG. OKT3 has proven to be useful for reversing these resistant rejections without causing significant morbidity from infection or death.",
author = "Douglas Norman and John Barry and Bennett, {W. M.} and M. Leone and K. Henell and B. Funnell and B. Hubert",
year = "1988",
language = "English (US)",
volume = "11",
pages = "90--93",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy

AU - Norman, Douglas

AU - Barry, John

AU - Bennett, W. M.

AU - Leone, M.

AU - Henell, K.

AU - Funnell, B.

AU - Hubert, B.

PY - 1988

Y1 - 1988

N2 - Thirty-one recipients of cadaver kidney transplants were given OKT3 monoclonal anti-T cell antibody for rejection treatment after conventional therapy had failed. Seventy-four percent of steroid or steroid and antithymocyte globulin (ATG) resistant rejections reversed with a standard course of OKT3. Rejections reversed in 85% of 26 patients treated within 90 days of transplantation. Late rejections treated more than 90 days after transplantation were poorly responsive to OKT3 and graft survival for this group of five patients was poor (20%). However, for those patients treated with OKT3 for early resistant rejection, actuarial 4-year graft survival was 66%. Actuarial 4-year patient survival was 97%, and the incidence of serious infection was low. Acute rejections in cadaver transplantation are common and a small percentage of rejections are resistant to steroids and ATG. OKT3 has proven to be useful for reversing these resistant rejections without causing significant morbidity from infection or death.

AB - Thirty-one recipients of cadaver kidney transplants were given OKT3 monoclonal anti-T cell antibody for rejection treatment after conventional therapy had failed. Seventy-four percent of steroid or steroid and antithymocyte globulin (ATG) resistant rejections reversed with a standard course of OKT3. Rejections reversed in 85% of 26 patients treated within 90 days of transplantation. Late rejections treated more than 90 days after transplantation were poorly responsive to OKT3 and graft survival for this group of five patients was poor (20%). However, for those patients treated with OKT3 for early resistant rejection, actuarial 4-year graft survival was 66%. Actuarial 4-year patient survival was 97%, and the incidence of serious infection was low. Acute rejections in cadaver transplantation are common and a small percentage of rejections are resistant to steroids and ATG. OKT3 has proven to be useful for reversing these resistant rejections without causing significant morbidity from infection or death.

UR - http://www.scopus.com/inward/record.url?scp=0023857054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023857054&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 90

EP - 93

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -